Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: SnowShredder who wrote (689)	9/10/1999 11:35:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 4474

>> (don't mind me just thinking online ; ) << GUFFAW! Where'd..... good thought, but I don't know which components are retained in the hybrid vectors...... aren't they the relatively non-immunogenic ones? Isn't that part of the point of the hybrid? Way outta my field of expertise here. Mike..... APC is "antigen presenting cell", I presume. See VLTS (the new PEGylation subsidiary in England) collaboration with ONXX for attempts to "tolerize" to adeno. Cheers! Rick